Paper Alert: Verubecestat EPOCH Findings Published
The drug had no effect on any clinical measure, while there were side effects such as rashes, insomnia, and thoughts of suicide.
ALL NEWS
6538 RESULTS
Sort By:
- Most Recent
- Most Commented
New Alzheimer’s and Parkinson’s Immunotherapy Data at AAN
Biogen showed results from clinical trials of anti-Aβ and anti-α-synuclein antibodies at the American Academy of Neurology annual meeting.
Oligodendrocytes Seem to Imprint Specific Alter Ego on α-Synuclein
Aggregates that form inside, or just pass through, oligodendrocytes take on the properties of the virulent strain that gives rise to multiple system atrophy.
“Nanosweeper” Brushes Aβ into Cellular Dustbins
Engineered nanoparticles snatched extracellular Aβ, ferried it into cells, and switched on autophagy, clearing the peptide from the brains of mice. Would this work as a drug?
Bad Synergy—Together, Vascular Problems and Aβ Hasten Memory Slippage
High vascular risk scores and Aβ burden independently associate with cognitive decline, but combined, they speed things up.
As RNA Therapies Come of Age, Efficacy Remains Weak
At AAN, the latest data from Phase 3 trials and open-label extensions of RNA-targeting therapies reveal a bit of benefit, but no cure.
American Academy of Neurology 2018 Annual Meeting
As RNA Therapies Come of Age, Efficacy Remains Weak At AAN, Sights Set on Antisense Therapies for Diseases of the Brain New Alzheimer’s and Parkinson’s Immunotherapy Data at AAN Will RNA molecules that bump up or tamp down gene expression live up to their
Culling Connection From Chaos, Alzheimer’s Genetic Network Study Pins PLXNB1 and INPPL1
Making deeper inroads into Alzheimer’s systems biology, groups of genes co-expressed in the cortex associated with clinical and pathological traits of the disease, notably the slope of cognitive decline.
2018 Alzheimer’s Disease Research Summit
Big Data Was the Big Theme at Shortened NIH Summit NIH Summit Wraps Up with Recommendations for Research 2018 Alzheimer’s Disease Research Summit
Dipeptide Repeats May Hobble Ribosomes in C9ORF72-FTD Patient Brain
Though the dipeptides interacted with many proteins in cell culture, they associated specifically with ribosomes in the human brain.
A Delicate Frontier: Human Microglia Focus of Attention at Keystone
Working with human microglia is fraught with technical challenges, but that didn’t stop researchers at Keystone from sharing a flurry of data on how these cells act in neurodegenerative disease.
Keystone Joint Symposia—Advances in Neurodegenerative Disease Research and Therapy / New Frontiers in Neuroinflammation: What Happens When CNS and Periphery Meet?
A Delicate Frontier: Human Microglia Focus of Attention at Keystone TREM2: Diehard Microglial Supporter, Consequences Be DAMed ApoE Has Hand in Alzheimer’s Beyond Aβ, Beyond the Brain Synaptic Tau Clangs the Dinner Bell for Hungry Microglia VCAM1: Gateway
TREM2: Diehard Microglial Supporter, Consequences Be DAMed
At Keystone, the work of several groups painted TREM2 as a dedicated supporter of microglial function across neurodegenerative disease models, including those for ALS.
ApoE Has Hand in Alzheimer’s Beyond Aβ, Beyond the Brain
At a Keystone meeting, researchers agreed that ApoE stokes damaging neuroinflammation in response to tau pathology. The E4 allele ramped up cholesterol biosynthesis in microglia and astrocytes, and even promoted neuronal damage when expressed outside of the brain.
Gene Therapy Treats Mouse Models of Gaucher’s Disease
In knockouts that model the most severe form of Gaucher’s disease, replacing one gene calms neuroinflammation, reduces neurodegeneration, and extends lifespan.
Current Filters
No filters selected